# Specification Quality Checklist: Approval Limits by Role

**Purpose**: Validate specification completeness and quality before proceeding to planning

**Created**: 2026-10-20

**Feature**: [spec.md](../spec.md)

## Content Quality

- [x] No implementation details (languages, frameworks, APIs)
- [x] Focused on user value and business needs
- [x] Written for non-technical stakeholders
- [x] All mandatory sections completed

## Requirement Completeness

- [x] No [NEEDS CLARIFICATION] markers remain
- [x] Requirements are testable and unambiguous
- [x] Success criteria are measurable
- [x] Success criteria are technology-agnostic (no implementation details)
- [x] All acceptance scenarios are defined
- [x] Edge cases are identified
- [x] Scope is clearly bounded
- [x] Dependencies and assumptions identified

## Feature Readiness

- [x] All functional requirements have clear acceptance criteria
- [x] User scenarios cover primary flows
- [x] Feature meets measurable outcomes defined in Success Criteria
- [x] No implementation details leak into specification

## Notes

- Iteration 1 failed "Requirements are testable and unambiguous": "up to 50,000" did not say whether 50,000 itself is allowed, and the first approver above 500,000 was unspecified. Both resolved in the Clarifications session (inclusive limits; first approver may be Manager or Director).
- Iteration 1 failed "Scope is clearly bounded": the fate of the existing Approver and Admin roles was open. Resolved: Approver retired, Admin cannot approve.
- FR-007 mentions "signed-in session"; kept because it is a security requirement visible to the business (who is acting), not an implementation choice.
- All items passed after iteration 2.
- Iteration 3 (after `/speckit-analyze`): "Requirements are testable and unambiguous" was re-opened for FR-001 (Manager may give a first approval above 500,000 but not a final one above 50,000) and for the undefined behaviour above 500,000 before US2. Both resolved (FR-001 reworded, interim behaviour specified); all items pass again. Details in [analysis.md](../analysis.md).
